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Summary
Dengue is a major global disease requiring improved treatment and prevention strategies. The
recently licensed Sanofi Pasteur Dengvaxia vaccine does not protect children under the age of
nine, and additional vaccine strategies are thus needed to halt this expanding global epidemic.
Here, we employed a molecular engineering approach and plant expression to produce a
humanized and highly immunogenic poly-immunoglobulin G scaffold (PIGS) fused to the
consensus dengue envelope protein III domain (cEDIII). The immunogenicity of this IgG Fc
receptor-targeted vaccine candidate was demonstrated in transgenic mice expressing human
FccRI/CD64, by induction of neutralizing antibodies and evidence of cell-mediated immunity.
Furthermore, these molecules were able to prime immune cells from human adenoid/tonsillar
tissue ex vivo as evidenced by antigen-specific CD4+ and CD8+ T-cell proliferation, IFN-c and
antibody production. The purified polymeric fraction of dengue PIGS (D-PIGS) induced stronger
immune activation than the monomeric form, suggesting a more efficient interaction with the
low-affinity Fcc receptors on antigen-presenting cells. These results show that the plant-
expressed D-PIGS have the potential for translation towards a safe and easily scalable single
antigen-based tetravalent dengue vaccine.
Introduction
Dengue infection poses a significant health risk with almost a
hundred million cases worldwide, of which half a million are
severe (Bhatt et al., 2013), characterized by organ dysfunction,
increased vascular permeability, haemorrhagic fever and den-
gue shock syndrome. To counter this expanding global health
threat, better case identification, improved patient manage-
ment and new preventive strategies are all urgently needed. A
major breakthrough in vaccine development occurred recently
with the licensing of the CYD tetravalent dengue vaccine in
several countries, following two large efficacy trials in Asia and
South America (Capeding et al., 2014; Watts et al., 1998).
However, the Sanofi Pasteur produced Dengvaxia (as it is
commercially known) is only partially effective against serotype
2 and most importantly contraindicated in children under the
age of nine (Hadinegoro et al., 2015), due to suboptimal
responses in this age population and risk of antibody-
dependent enhancement of infection (ADE). Also, while the
vaccine has been cautiously endorsed by the WHO (Wilder-
Smith et al., 2016), there remain a number of other issues with
this vaccine, including its stability, cost-effectiveness and
affordability (Deen et al., 2016; Godoi et al., 2017; Harapan
et al., 2017; Shafie et al., 2017).
Meanwhile, several other vaccine candidates have either
progressed to clinical trials or are in the late stages of preclinical
development. Thus, one of the most advanced alternatives to
Dengvaxia is the DENVax vaccine developed by Takeda Vaccines
Inc (Brewoo et al., 2012; Osorio et al., 2011), currently under-
going phase 2 trials in Asia and Latin America (Saez-Llorens et al.,
2017). Similarly, the LAV Delta 30 (NIAD/Butantan) dengue
vaccine has completed phase 1 clinical trials (Durbin et al., 2011)
and is about to enter phase II trials. All three aforementioned
tetravalent vaccines are based on attenuated viral backbone
platforms and while this may be an advantage when comparing
their performance in different geographical areas and age
populations, there is a certain element of overlap which may
lead to common safety, stability and cost-effectiveness issues.
There is a need for additional and preferably complementary
vaccine approaches which could be used instead of or alongside
one of the viral tetravalent vaccines to achieve a satisfactory level
of protection in all subjects.
Several promising nonlive subunit dengue vaccine candidates
have been reported, including DNA vaccines (Poggianella et al.,
2015; Porter and Raviprakash, 2015), nanoparticle formulations
(Swaminathan et al., 2016) and lipidated dengue antigens
(Chiang et al., 2016). These and other preclinical candidates
currently being considered are necessary for continuous feeding
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of the dengue vaccine pipeline until an effective vaccine strategy
against this global pandemic is finally attained. Our own
approach has been to evaluate novel dengue subunit vaccine
candidates expressed in genetically modified plants and designed
to be inherently self-adjuvanting (Kim et al., 2015, 2016). Many
potential biologics have been expressed in genetically modified
plants (Arntzen, 2015) and this trend is likely to continue with the
increasing demand for cheaper medicines produced at large
scales. One of the more successful recent examples reaffirming
the growing promise of plant-made biologics is highlighted by the
success story of ZMappTM as a potentially life-saving drug during
the Ebola outbreak of 2014–2016 (Lyon et al., 2014). Impor-
tantly, unlike bacteria, plants are capable of performing post-
translational modifications in proteins which makes them
amenable for expression of complex proteins such as antibodies
and the Fc-antigen fusion proteins described here.
Fusion proteins based on immunoglobulin Fc domain have
received considerable attention over the past two decades, as
either therapeutic tools or potential vaccine delivery platform.
Currently, Fc-fusion-based biologics are some of the biggest
profit grossing drugs in pharmaceutical industry (Czajkowsky
et al., 2012). However, the use of Fc-fusion proteins in vaccine
development has lagged behind. Indeed, several reports describe
the use of fusion proteins as vaccine constructs against a number
of conditions including infections, allergies and cancer (reviewed
in Czajkowsky et al., 2012), but to our knowledge, no vaccine
based on Fc-fusion proteins has been licensed yet for any of these
conditions.
Nevertheless, Fc-fusion proteins have considerable vaccine
potential, from both an immunogenic and a safety point of view.
Not only are they inherently safe as nonlive, protein subunit
vaccines, but their potential self-adjuvanting nature means that
the need for exogenous adjuvants is reduced. The targeting of Fc
receptors on antigen-presenting cells (APCs) leads to enhanced
antigen uptake and processing, while their polymeric nature
provides an additional antigen depot effect, both properties
ordinarily conferred by adjuvants in conventional vaccines.
Modelled on the early work of Mekhaiel et al. (2011), we have
previously tested the immunogenic potential of the polymeric
immunoglobulin scaffold (PIGS) as a molecular platform for
delivery of the dengue virus envelope domain III in mice and
found that they were highly immunogenic (Kim et al., 2017).
Here, we provide important new evidence for the substantial
vaccine potential of the fully humanized version of the dengue
PIGS (D-PIGS) that is critical for translation of this technology
towards application in humans.
Results
D-PIGS are immunogenic in human adenotonsillar tissue
We generated dengue Fc-fusion proteins based on human IgG1
heavy chain and consensus EDIII domain of dengue envelope
protein, by replacing the variable region with the cEDIII and
linking it to Cc2 and Cc3 domains by a short peptide derived
partly from Cc1 domain and partly from the hinge region. The
ltp is genetically linked at the C0-terminus. This fusion protein can
then form monomers or polymers resembling polymeric IgM. One
of the key advantages of the Fc-fusion proteins over free antigens
is their capacity to bind to the Fc receptors on APCs and thus
enhance antigen uptake and subsequent processing and presen-
tation. Furthermore, while monomeric Fc-fusion proteins can bind
only to the high-affinity receptor (FccRI), the polymeric versions
(here termed ‘D-PIGS’) can bind to both high- and low-affinity
receptors (Figure 1a), thus substantially enhancing their overall
immunogenic potential. We validated this concept by testing the
immunogenicity of either antigen alone, the monomeric fusion
protein or the D-PIGS in human tonsillar tissue cell cultures from
patients undergoing elective tonsillectomy and with no previous
dengue exposure. CD4+ and CD8+ T-cell proliferative responses in
CFSE-labelled cell cultures were measured by flow cytometry
(gating strategy shown in Figure S6) as well as IFN-c production.
As shown in Figure 1b, while both the monomer and polymers
induces T-cell responses and IFN-c production significantly above
that induced by cEDIII antigen alone (P < 0.05 and 0.01,
respectively), D-PIGS were significantly more efficient in doing
so than the monomers (P < 0.05). Moreover, D-PIGS also induced
higher antigen-specific IgG response in these cultures over 2-
week incubation period. Taken together, these findings show
that this fully humanized dengue vaccine candidate is immuno-
genic in human immune tissues, inducing both cellular and
humoral immune responses in the absence of exogenous
adjuvants.
Plant expression and purification of D-PIGS
Molecular cloning of mouse and human versions of D-PIGS is
described previously (Kim et al., 2017). Human D-PIGS were
transiently expressed in Nicotiana benthamiana plants following
infiltration with recombinant agrobacteria and purified by protein
A chromatography. This expression system yielded on average
17 mg protein/kg fresh weight plant tissue. Both wild type and a
ΔXF glycosylation mutant of N. benthamiana plants lacking
fucose and xylose glycosylation (Strasser et al., 2004) were used,
but the latter version was used in all experiments due to its
enhanced receptor binding function (Figure S1). D-PIGS were
analysed by SDS-PAGE electrophoresis and Western blotting, as
well as HPLC. Under reducing conditions (R), D-PIGS yielded a
dominant 40-kDa protein band reactive with both antidengue
and anti-Fcc antibodies, consistent with a single (S) cEDIII-Fc-
fusion protein chain (Figure 2a, lane 2). However, under nonre-
ducing conditions (NR), additional protein bands were revealed,
including an 80-kDa band likely representing the monomer (M),
and a dominant diffuse band of 160 kDa and above likely
representing a mixture of dimers (160 kDa) and polymers
(480 kDa expected molecular weight), although this could not
be discerned clearly from the gel due to insufficient resolution.
Negative (wild-type plant extract, lane 1) and positive controls
(lane ‘PC’) represented by recombinant cEDIII and human IgG1
were included for comparisons.
As the SDS-PAGE analysis revealed a mixture of monomeric/
single chain and polymeric molecular species in the D-PIGS
preparation, we next fractionated the low and high molecular
weight forms by HPLC (Figure 2c). The HPLC profile indicated
presence of several protein peaks that corresponded to single
chain (S), monomer (M) and polymers (P). These could be
separated into two main fractions corresponding to a dominant
single polymer peak and a mixture of monomer and single chain
(Figure 2c, middle panel). The retention times for these protein
fractions were compared to those of molecular weight standard
proteins (bottom panel) and while M and S eluted as 80- and 40-
kDa protein peaks, the polymeric fraction presented as approx-
imately a 680-kDa protein, which is somewhat higher than the
theoretical weight of the D-PIGS hexamer (480 kDa), even when
accounting for 12 carbohydrate chains present on the IgG1-Fc
(equating to approximately 36 kDa). The larger than expected
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size of the D-PIGS could be simply an anomaly of the HPLC system
and the molecular standards we used or perhaps altered
behaviour due to the presence of multiple carbohydrate chains.
This is partly supported by SDS-PAGE analysis of the separated
fractions that showed the presence of monomers and single
chains in the low molecular weight fraction (lane 4), and a diffuse
polymeric protein band (lane 3) which is significantly smaller than
the 970-kDa pentameric IgM (lane 2) (Figure 2b) but bigger than
the 380-kDa human sIgA (lane 1) (Figure 2b). The separated
polymeric fraction was stable and showed no degradation or
change in the ratio of the two molecular forms (hexamers and
higher polymers) upon 24-h storage at room temperature, +4 or
20 °C (Figure S2).
Analysis of D-PIGS binding to Fc gamma receptors
We next tested D-PIGS binding to high- and low-affinity Fc
gamma receptors in comparison with human IgG1, by surface
plasmon resonance analysis (Biacore). Two assays were per-
formed, as illustrated in Figure 3a. First, increasing concentrations
of human CD64 and CD16a were used as analytes to measure
the kinetics of the FcR/Fc interaction. Both D-PIGS and hIgG1
displayed rapid binding kinetics and slow dissociation from the
high-affinity receptor CD64 (Figure 3b), resulting in calculated
affinity constants well above 109 (right panel and Table S1). In
contrast, when tested for binding to the low-affinity receptor
CD16a, only D-PIGS displayed prolonged dissociation kinetics in
keeping with significant binding, whereas hIgG1 dissociated
extremely rapidly, indicating a very low affinity of binding (right-
hand panel). These findings are consistent with previous reports
that the removal of core fucose in either the plant or mammalian
linkages increases affinity for Fc receptors including CD16a
(Forthal et al., 2010; Shields et al., 2002).
To determine whether D-PIGS complexes displayed enhanced
avidity in respect to FcR binding, we designed a reversed assay
layout (Figure 3a, right panel) with the FcR immobilized to the
chip via an anti-his antibody and the unfractionated D-PIGS
complex supplied in the fluid phase (Figure 3c). A receptor
density of 200 pg/mm2 was chosen to allow multiple interactions
between FcRs and Fc domains in the D-PIGS to occur. Due to the
extremely high affinity of CD64 to hIgG1 and to the D-PIGS (left
panel), both samples did not dissociate from the surface for the
duration of the injection. In contrast, for both low-affinity
receptors, D-PIGS remained bound while hIgG1 dissociated
within 5 s (CD32a) or at 58 s postinjection (CD16a). We repeated
this assay with D-PIGS material fractioned by HPLC (Figure 3d)
and observed that the polymer fraction was retained to CD16a
(time to 50% dissociation >600 s), while the M/S fraction was
released with a similar decay profile to hIgG1 (time to 50%
dissociation 61 and 58 s, respectively). Interaction with CD32a
and the high-affinity receptor CD64 was also markedly stabilized
in the polymeric fraction (Tables S1 and S2). These data show
that D-PIGS polymers are capable of establishing long-lasting
interactions with low-affinity Fc receptors.
In vitro characterization of D-PIGS
Dengue PIGS were tested for capacity to bind to C1q component
of the complement and to the U937 monocyte cell line expressing
the Fc gamma receptors. As shown in Figure 4a, D-PIGS bound to
C1q component of the complement in the concentration-
dependent manner, as would immune complexes do, while
monomeric hIgG1 did not. Interestingly, purified polymers bound
better than the unfractionated D-PIGs, while the monomer/single
chain fraction showed little to no binding, as expected. This
finding confirms the presence of functional polymers in the D-PIGS
(a)
(b)
Figure 1 Dengue poly-immunoglobulin G
scaffold (D-PIGS) induce cellular and humoral
immune responses in human adenoid/tonsil
cultures. (a) Schematic representation of the
monomeric and polymeric human IgG1-cEDIII
fusion protein and its interaction with high and
low-affinity Fc gamma receptors on antigen-
presenting cells; further details of the structure of
these molecules are described in Kim et al. (2017).
Red represents cEDIII domain, while dark and light
blue indicate CH2 and CH3 domains of human
IgG1, respectively. (b) Immunogenicity of D-PIGS
in human tonsil cultures; shown are flow
cytometric data of CFSE staining expressed as
percentages of antigen-specific CD4- and CD8-
proliferating cells, IFN-c and IgG concentrations in
culture supernatants, induced by cEDIII alone,
monomer/single chain (M/S) and polymer (P,
D-PIGS). Data are shown as means  SEM from
eight patients. Statistical analysis was performed
by ANOVA and Dunnett’s test, where *indicates
differences <0.05 and **<0.01.
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preparation and is an indication of their immunogenic potential.
Furthermore, D-PIGS bound efficiently to the surface of U937 cells
(used here as a model APC) and this binding was comparable to
that of heat-aggregated human IgG (Figure 4b). Although hIgG1
also showed some binding (due to the presence of CD64 on these
cells), this was significantly weaker compared to D-PIGS. However,
in a direct comparison between unfractionated and fractionated
D-PIGS, no significant differences could be observed in binding to
U937 cells (Figure S3a). Taken together, these two in vitro assays
demonstrate the functionality of D-PIGS and their capacity to
interact with the immune cells and molecules.
IgG response after immunization of CD64 transgenic
mice with D-PIGS
Having confirmed the functionality of D-PIGS molecules in vitro,
we next tested their immunogenicity in mice transgenic for
human high-affinity receptor CD64. Mice were immunized three
times in total, and after each immunization, blood samples were
taken for analysis of serum IgG responses. As can be seen in
Figure 5a, no significant responses were detected after the first
immunization for any of the experimental groups. However, after
second immunization, IgG was detected in all groups except in
mice immunized with cEDIII alone or in wild-type mice immunized
with D-PIGS. The response was further enhanced after the third
immunization, with the groups co-administered with alum
showing the highest responses at the serum dilution used
(1 : 1000). Interestingly, D-PIGS induced a low level response in
wild-type mice, possibly due to cross-reactivity with mouse Fc
receptors or other immune complex capturing mechanisms. We
next determined endpoint titres in the immune sera (Figure 5b)
and these were 1 : 9000 for cEDIII alone and 1 : 81 000 for
D-PIGS with or without alum. Similar to D-PIGS, the monomeric
form also induced a comparable IgG response in CD64 transgenic
mice, signifying the role of the high-affinity receptor in mediating
uptake of these fusion proteins (Figure S3b). We further analysed
the relative proportion of IgG1 and IgG2a subtypes in the IgG
response, which is an indication of Th2 or Th1 bias. As shown in
Figure 5c and d, IgG1 showed significantly higher endpoint titres
compared to IgG2a which suggests a possible Th2 bias, although
some Th1 response at least is also evident.
DENV neutralizing capacity of D-PIGS-induced
antibodies
As neutralizing antibodies are an essential component of a
protective immune response against dengue infection, we next
tested the neutralizing potential of the immune sera against all
four serotypes of the dengue virus. This was performed in the
standard plaque reduction assay by determining FRNT50 values
against each serotype. The results are shown in Figure 6. Sera
from mice immunized with cEDIII alone showed neutralizing
potential only against DENV4 (4/5) while failing to neutralize any
other serotypes. Sera from mice immunized with D-PIGS showed
a superior neutralizing potential against all serotypes, although
DENV3 was neutralized robustly by serum from one animal only,
while other four animals showed borderline neutralizing activity
(50% inhibition was achieved only with the first serum dilution of
1 : 50). The titration curves show the range of focus reduction
neutralization test (FRNT) titres and serum dilutions. The titres of
all the non-neutralizing mice were scored arbitrarily as 1 : 25 with
50 being the minimum starting serum dilution. Overall, the D-
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Figure 2 Expression, purification and molecular fractionation of dengue poly-immunoglobulin G scaffold (D-PIGS). (a) D-PIGS were expressed in Nicotiana
benthamiana plants and the extracts analysed by Western blotting under reducing (R) or nonreducing (NR) conditions using antidengue or anti-Fc gamma
antibodies. ‘PC’ is the positive control (recombinant cEDIII or human IgG1, respectively). Lane 1: wild-type plant extract; lane 2: unfractionated D-PIGS.
Positions of the single chain (S), monomer (M) and polymers (P) are indicated. (b) SDS-PAGE and Commassie staining of fractionated D-PIGS. Lanes: 1.
Commercial (Sigma) human sIgA; 2. Commercial (Sigma) human IgM; 3. Polymers and 4. Monomers. The schematics bellow indicate the expected
molecular sizes for each fraction. (c) HPLC profile of D-PIGS. Unfractionated (upper panel) and fractionated (middle panel) D-PIGS. Indicated retention times
were used to estimate the molecular weights of each fraction, based on gel filtration protein standards (bottom panel). The fractionated D-PIGS were used
in immunogenicity studies with tonsillar cultures (Figure 1b).
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PIGS-vaccinated mice exhibited strong neutralizing antibodies
titre with mean titre of 1 : 257 (1 : 68–1 : 636) for DENV1,
1 : 115 (1 : 70–1 : 218) for DENV2, 1 : 233 (1 : 50–1 : 970) for
DENV3 and 1 : 899 (1 : 79–1 : 1440) for DENV4. In contrast,
although mice immunized with D-PIGS with alum showed
comparable antibody titres to D-PIGS alone, this was not reflected
in enhanced neutralizing activity, which in fact was lower.
Similarly, addition of alum did not increase DENV neutralizing
activity of sera despite increased antibody titres (Figure S4). It
appears that the presence of alum somewhat diminished the
neutralizing activity of the immune sera, possibly reflecting
qualitative differences conferred by the two immunization
regimens.
Cellular immune response to D-PIGS immunization
We next investigated cellular responses to our vaccine. Emerging
evidence suggests that polyfunctional T cells in particular play a
protective role in dengue immunization (Yauch et al., 2009).
Therefore, CD4+ and CD8+ T cells were assessed for production
of combinations of the effector cytokines IFN-c, IL-2, IL-17A and
TNF-a after antigen recall (gating strategy shown in Figure S5). As
can be seen in Figure 7a, cEDIII alone induced 20.9% and 6.29%
CD4+ and CD8+ polyfunctional T cells, respectively. A striking
observation was the total lack of quadruple cytokine producers in
the CD8 compartment. Interestingly, the monofunctional pheno-
type in the cEDIII immunization group was defined by a strong
IFN-c signature. D-PIGS alone induced 22.91% CD4+ and 7.79%
CD8+ polyfunctional T cells, and this was enhanced even further
with adjuvant, leading to an increase of 24.86% CD4+ and
18.39% CD8+ polyfunctional T cells.
Given the importance of CD8+ T cells in protection against
DENV—and the observation that D-PIGS induced quadruple
cytokine producing cytotoxic cells—we further probed the
CD8+ memory T-cell compartment in response to D-PIGS
Fcγ Rs
D-PIGS
Protein A
Sensor chip
Affinity (1:1) Avidity (1: multi)
Sensor chip
Fc Rs
D-PIGS
α-his Ab
γ
(a)
(b)
(c)
Figure 3 Biacore analysis of binding of dengue poly-immunoglobulin G scaffold (D-PIGS) to Fc gamma receptors. (a) Schematic representation of affinity
vs avidity measurement. (b) Affinity measurement of the interaction between immobilized (200RU) unfractionated D-PIGS and hIgG1 to CD64 (120, 60, 30,
15 nM) and CD16a (800, 400, 100, 25, 12.5 nM). The panel on the right indicates calculated affinity constants (KD) for each interaction as calculated using
either the 1 : 1 Langmuir model (CD64) or the ‘two-state reaction’ model (CD16a). (c) Binding (avidity) of unfractionated D-PIGS and human IgG1 to his-
tag captured (immobilized) CD64, CD32a and CD16a receptors at a surface density of 200 pg/mm2.
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immunization. Splenocytes from immunized mice were cultured
for several more days in the presence of recall antigen or positive
control (recombinant anti-CD3 antibody) and then assessed for
expression of the proliferation marker Ki67. As shown in
Figure 7b, there was a dramatic increase in the overall percentage
of proliferating cytotoxic cells in splenocytes from mice immu-
nized with D-PIGS compared to cEDIII antigen alone (13.4%
Ki67+ vs 28.4% Ki67+ cells, respectively). Consistent with the
polyfunctionality, this was further boosted in the alum immu-
nization group (34.2% Ki67+ cells), although cEDIII adjuvanted
with alum showed a comparable increase in proliferation
(32.6%). Proliferating cells were then examined for memory T-
cell phenotype, using CD44 and CD62L to denote T central
memory (TCM: CD44
hi CD62Lhi), T effector memory (TEM:
CD44hi CD62Llo) and na€ıve T cells (TN: CD44
lo CD62Lhi). While
there were only minimal differences in the percentages of
proliferating TEM cells between immunization groups, there was
an approximately fourfold increase in the percentage of prolif-
erating TCM cells in D-PIGS (alum) compared to cEDIII alone.
Lastly, it was found that enhanced proliferation was associated
with a higher quantity of secreted IFN-c in the recall culture
(Figure S3c). It was therefore concluded that D-PIGS increased
the both the quality and magnitude of the cellular response, as
evidenced by increased T-cell function and proliferative capacity
of various memory subsets.
Discussion
We describe a novel vaccination approach against dengue
infection based on Fc-antigen fusion approach. We previously
expressed D-PIGS molecules based on murine IgG2a and showed
that they were highly immunogenic in mice (Kim et al., 2017). To
translate this promising vaccine approach into a potential dengue
vaccine candidate in humans, we generated the human version of
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Figure 5 IgG response in sera of CD64 Tg mice
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D-PIGS and purified them to a high degree of homogeneity. D-
PIGS were highly immunogenic in transgenic mice expressing
human IgG high-affinity receptor and more importantly in human
tonsil cultures. Thus, D-PIGS induced T-cell memory responses,
IFN-c production and neutralizing antibodies against all four
DENV serotypes. This nonlive, subunit dengue vaccine based on
the consensus EDIII domain and human IgG1 polymeric scaffold
has many potential advantages over the other vaccination
platforms, including simplicity of production, easy scalability,
minimal risk of contamination with animal pathogens, and most
importantly, it does not suffer from antigenic interference
typically associated with a conventional tetravalent vaccine. The
latter advantage is conferred by the use of consensus domain III
sequence that is expressed as a single protein fused to human
IgG1-Fc.
The role of EDIII in inducing neutralizing antibodies is some-
what paradoxical, in that human sera from dengue patients
appear to contain only a low proportion of such antibodies
directed to EDIII (Chen et al., 2016; Wahala et al., 2009; Williams
et al., 2012) and yet, there are a number of strongly neutralizing
monoclonal antibodies reported (Crill and Roehrig, 2001; Roehrig
et al., 1998; Shrestha et al., 2010; Sukupolvi-Petty et al., 2007).
While most of these monoclonal antibodies target linear epitopes,
some of the strongly neutralizing mAbs such as 2D22 target a
quaternary epitope on EDIII (Gallichotte et al., 2015). Similarly,
rabbit antisera targeted to EDIII was strongly neutralizing and
induced very little ADE, suggesting that EDIII may be used as a
subunit vaccine to induce an effective and safe antibody
response. This is consistent with the concept of unnatural
immunity, whereby natural infection does not seem to provoke
neutralizing anti-EDIII response while increasing the risk of cross-
reactivity and ADE, yet vaccine-induced EDIII antibodies may
confer protection. Indeed, a study of human antidengue neutral-
izing antibodies showed that they predominantly recognize
D-PIGS
- + alum
DEN1 1:257 (68-636) 1:152 (49-374)
DEN2 1:115 (70-218) 1:157 (49-587)
DEN3 1:233 (49-970) 1:371 (49-1013)
DEN4 1:899 (79-1440) Undetectable
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Figure 6 Neutralizing activity of dengue poly-
immunoglobulin G scaffold (D-PIGS) immune sera
from mice. Shown are the focus reduction
neutralization test scatter plots and the titration
curves from serial dilutions of immune sera from
five mice for cEDIII alone and for D-PIGS, with or
without alum. 50% neutralization cut-off
(perforated line) is indicated.
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complex epitopes present on the intact virions but not recombi-
nant envelope ectodomain protein (de Alwis et al., 2012). In this
study, we used a consensus domain III (Leng et al., 2009)
obtained by alignment of amino acid sequences from different
isolates of the four serotypes of dengue viruses, rather than the
mixture of four individual serotype-specific domains, thus simpli-
fying significantly the vaccine formulation.
Dengue PIGS induced strong antibody responses in transgenic
mice expressing human IgG high-affinity receptor (CD64).
Although both IgG1 and IgG2a were present, a much higher
titre of IgG1 was detected, suggesting a Th2 bias. Both
monomeric and polymeric D-PIGS were immunogenic in mice
(Figure S3b). This is in contrast with human immune response in
tonsil cultures which indicated polymer superiority in inducing an
IgG response and could be explained by only partial suitability of
the transgenic CD64 mouse model. As both monomer and
polymer can bind to high-affinity IgG receptor but only polymer
binds to the low-affinity receptors, the single receptor transgene
model may not be sufficiently discriminatory, unlike the human
tissue, which displays all the IgG receptors. Nevertheless, the
induced mouse cEDIII-specific antibodies were able to neutralize
dengue serotypes 1, 2 and 4 with similar efficiency, with only
DENV3 showing lower FRNT values. Interestingly, despite induc-
ing higher antibody titres to D-PIGS, addition of alum as the
CD4s CD8s(a)
(b)
Figure 7 Cellular immune responses induced by dengue poly-immunoglobulin G scaffold (D-PIGS). (a) T cells were assessed for polyfunctionality after
exposure to recall antigen in the CD4+ (left) and CD8+ (right) compartments. The gating strategy is shown in Figure S4. Pie charts depict sum total of 1
(blue), 2 (green), 3 (yellow) and 4 cytokine-positive (red) responses, with values for specific cytokine combinations shown below. (b) Splenocytes were
cultured for a further 5 days and assessed for intracellular expression of Ki67 in gated CD8+ cells, alongside extracellular levels of CD44 and CD62L. Shown
are representative plots of proliferating cells.
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adjuvant did not enhance neutralization potential of induced
antibodies and in fact, appeared to have a detrimental effect.
Although we have no experimental evidence, we speculate that
this is most likely due to qualitative differences in the functionality
of the induced antibodies.
The importance of T-cell responses in dengue infection has
been very much in focus recently. While effector T cells are
partially responsible for the immunopathology of dengue disease,
effective vaccine-induced protection depends on these cells. This
was elegantly demonstrated in experiments by Yauch et al.
(2009) who showed that depletion of CD4+ T cells during natural
infection had no effect on viral control, whereas depletion of this
subset during DENV peptide immunization led to a total loss of
vaccine-induced protection. Dengue induces a number of CD4+
T- and CD8+ T-cell epitopes to both structural and nonstructural
proteins recognized in mice (Rothman et al., 1996) and humans
(Weiskopf et al., 2015b,c). CD8+ T-cell responses (particularly of a
polyfunctional phenotype) are generally thought to play an
important role in controlling infection and thus the severity of the
disease, partly supported by experimental evidence (Gil et al.,
2009, 2014; Yauch et al., 2009). Although nonstructural proteins
are the dominant targets of the CD8+ T-cell responses (Weiskopf
et al., 2013), some CD8+ T-cell epitopes are present in DIII of the
envelope protein (Chiang et al., 2016; Weiskopf et al., 2015a). In
our studies, we detected cEDIII-specific both CD4+ and CD8+ T-
cell proliferation in tonsillar cell populations stimulated in vitro.
This proliferative response was associated with IFN-c production.
Interestingly, polymeric D-PIGS were more efficient in inducing
these cellular responses than the monomeric version, most
probably due to a more efficient binding of the Fc receptors, as
demonstrated in our in vitro Biacore assays. In our in vivo
experiments, D-PIGS were more adept than single antigen at
producing proliferative TEM and TCM responses, alongside
increased IFN-c production and a greater degree of polyfunc-
tionality. TCM are of particular interest as these memory cells can
serve as a long-lasting reservoir of immunological memory with
high proliferative capacity. Together, these human and mouse
cellular data underscore the immunological superiority of D-PIGS
over single antigen immunization.
The advantages of plants as an expression system have been
well documented. One of the key advantages is the capacity for
almost enormous scale-up production of pharmaceutical proteins
which may be required to meet ever increasing global demand.
Existing microbial systems simply cannot meet that demand
because they are either very expensive, or the proteins of interest,
such as antibodies and the Fc-fusion proteins described here, are
too complex to be made in such systems. Animal or human cell
cultures provide an alternative, but are expensive. Like animals,
plants are complex, multicellular organisms and their protein
synthesis is more similar to that of animals than those of bacteria
or other bio-microorganisms. To further reduce differences in
post-translational modification of plant-expressed proteins, vari-
ous genetic plant mutants have been generated, including the
delta XF tobacco line used in this study. Glyco-engineering in
plant is developed for pharmaceutical products and well docu-
mented (Forthal et al., 2010; Strasser, 2016). Thus, Strasser et al.
(2004) produced a triple knockout in Arabidopsis that downreg-
ulates b-(1,2) XylT and a-(1,3) FucT activity, resulting in the
absence of plant-specific glycans which are occasionally involved
in inducing glycan-specific IgE (Reusch and Tejada, 2015), and a
product that is much more similar to human glycoproteins. D-
PIGS without plant-specific fucose and xylose show higher affinity
for FccRIII than D-PIGS from wild-type N. benthamiana, and this is
consistent with the findings from another study reporting
enhanced binding to human FccRIII and antibody-dependent
cellular toxicity on glyco-engineered human IgG1 (Shields et al.,
2002). The D-PIGS molecules produced in delta XF plants as
described here could therefore be feasibly produced and purified
to a high degree of purity and homogeneity to meet the good
practice manufacturing requirements for safe human applica-
tions.
In conclusion, we described a novel plant-expressed subunit
vaccine candidate for dengue vaccination based on Fc-antigen
fusion protein approach that could potentially be used as a boost
to a viral-based dengue vaccine. Humanized D-PIGS show a
desirable immunogenic profile in mice transgenic for human IgG
Fc receptor and in human tonsil tissues and importantly, induce
neutralizing antibody responses and cellular immunity, which are
both required in a protective antidengue response. This novel
dengue vaccine candidate merits further evaluation as a boost to
Dengvaxia or DENVax in the nonhuman primate model of dengue
infection, to achieve complete protection against all for DENV
virus serotypes.
Materials and methods
Plant expression, detection, purification and
fractionation of D-PIGS
Vector construction for D-PIGS, agro-infiltration of N. benthami-
ana plant leaves, purification and detection by SDS-PAGE and
Western blotting, as well as fractionation of low and high
molecular weight forms, were all described in detail previously
(Kim et al., 2017). Briefly, the agrobacteria (GV3101 strain)
transformed with D-PIGS constructs and human J chain (co-
expression to facilitate the assembly of PIGS into polymers) were
cultured at 28 °C in YENB medium containing antibiotics (50 lg/
mL each of carbenicillin, kanamycin and rifampicin) for 2 days.
Cells were collected by centrifugation and infiltrated into tobacco
leaves. Leaf extracts were prepared 7 days later and proteins
separated on a 4%–12% Bis-Tris SDS-PAGE gel (Thermo Fisher,
Paisley, UK), followed by Coomassie Blue staining or blotting onto
a nitrocellulose membrane. Blots were probed with peroxidase-
conjugated anti-human IgG antiserum (1 : 1000 dilution; The
Binding Site Birmingham, UK) for detection of the IgG Fc portion,
or with antidengue virus monoclonal antibody (1 : 2500 dilution;
Bio-Rad AbD Serotec Kidlington, UK) followed by anti-mouse IgG
peroxidase-conjugated antiserum (1 : 1000 dilution; The Binding
Site). For purification of D-PIGS, standard protein A chromatog-
raphy procedure was applied, followed by concentrating the
protein by ultrafiltration (Centricon, Merck-Millipore, Watford,
UK) to 1 mg/mL. For some experiments, purified D-PIGS were
fractionated by HPLC on a Shimadzu LC2010AHT system (Milton
Keynes, UK). Separation was achieved in phosphate-buffered
saline (PBS) at a flow rate of 1 mL/min. As reference, the Bio-Rad
GFC Standards were used.
FccR binding kinetics
The affinity and avidity of the D-PIGS complexes in binding to
human Fcc receptors were measured using a Biacore X100
instrument (GE Life Sciences, Little Chalfont, UK). For the affinity
measurements, 5000 relative units (RU) of a protein A (P6032,
Merck, Poole, UK) in pH 5.5 acetate buffer (GE Life Sciences) was
immobilized on both flow channels of a CM5 sensor chip using
amine coupling chemistry (His capture kit; GE Life Sciences). For
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each cycle, 200 RU of the sample (PIGS or hIgG1) was captured on
flow channel 2. The analyte, either recombinant human CD16a
(4325-FC; R&D Systems, Abingdon, UK) or recombinant human
CD64 (1257-FC-050; R&D Systems), was injected in a concentra-
tion series from 12.5 to 800 nM over both flow channels with a
contact time of 60 s and a flow rate of 50 lL/min and dissociation
monitored for 200 s. Regeneration of the surface was achieved by
two 30-s pulses of 10 mM glycine pH 1.5.
Data were fitted to the predefined ‘two-state interaction’
model for CD16a (Heider et al., 2011)and the ‘1 : 1 interaction’
model for CD64.
For the avidity assay, 12 000 RU of an anti-his antibody was
immobilized on both flow channels of a CM5 sensor chip using
amine coupling chemistry (His capture kit; GE Life Sciences). For
each sample, recombinant human CD16 or CD64 (as above)
diluted to 2 lg/mL in HBS-EP+ running buffer was captured on
flow channel 2 to a level of 200 RU. Samples (1 lM, 500 nM and
166.7 nM for CD64, CD32a and CD16a, respectively) were
injected over both flow channels with a contact time of 80 s
and a flow rate of 30 lL/min, and dissociation was monitored for
at least 500 s. Regeneration of the surface was achieved by a 30-s
pulse of 10 mM glycine pH 1.5.
Immunization of mice
For immunization with D-PIGS, 12- to 20-week-old inbred male
and female FccRI/CD64 mice were used. These mice were
originated in 1996 (Heijnen et al., 1996) and a colony is kept
and bred at St George’s since 2010 under the establishment
licence. The mice were kept under defined environmental
conditions, and all experimental work was approved by St
George’s Ethics Committee and the UK Home Office. Five mice
per group (both males and females, aged 8–20 weeks) were
immunized subcutaneously in the base of tail with 25 lg of D-
PIGS in 100 lL, with or without aluminium hydroxide gel (Sigma).
Control mice were immunized with saline solution or with 6 lg
cEDIII alone (equivalent amount of the antigen within D-PIGS).
Mice were immunized two more times, at weeks 2 and 4, and
were bled after each immunization to monitor the antibody titres.
At week 6, mice were sacrificed and bled by cardiac puncture and
the spleens were collected for analysis of T-cell responses.
Focus reduction neutralization test
Neutralization capacity of sera samples against dengue 1–4
(DENV1 West Pac/74—Nauru 1974; DENV2 S-16803—Thailand
1974; DENV3 CH 53489—Thailand 1973; DENV4 TVP-360/
S341750—Columbia 1982) was determined by FRNT on Vero
cells (ATCC) seeded in 96-well flat-bottom plates at a density of
20 000 cells per well in DMEM supplemented with 10% FBS.
Cells were cultured for 24 h before infection. Sera were thawed
and heat-inactivated at 56 °C for 30 min and serially diluted from
1 : 25 to 1 : 3200 in 100 lL Opti-MEM (Thermo Fisher, Hemel
Hempstead, UK) serum-free medium and an equal volume of
dengue virus containing 200 PFU was added and incubated for
1 h at 37 °C in 96-well U-bottom cell culture plates. Vero
monolayer was then infected with 50 lL of the serum–virus
mixture and further incubated for 1 h at 37 °C making the final
serum dilution to 1 : 50 in the first well and final PFU to 100. The
cells were incubated at 37 °C for 3 days with an overlay of 2%
methylcellulose (Sigma) in Opti-MEM containing 20 lg/mL of
ciprofloxacin (Sigma) and 2.5 lg/mL of amphotericin B (Himedia,
Mumbai, India). At termination, cells were fixed and stained with
anti-Flavivirus Group Antigen Antibody, clone D1-4G2-4-15
(Merck-Millipore, Watford, UK) at 1 : 2500 dilution followed by
HRP-linked anti-mouse IgG (Cell Signaling Danvers, MA). Foci
were developed with TrueBlue Peroxidase (KLP). Separate plates
were used for each serotype to account for different time
intervals required for colour development. FRNT50 was calculated
where 50% reduction in foci was observed as compared to
control wells (virus only).
Intracellular cytokine staining and flow cytometry
T-cell polyfunctionality was measured as previously described
(Kim et al., 2017). Briefly, splenocytes were stimulated with 5 lg/
mL cEDIII for 4 h in the presence of 5 lg/mL brefeldin A. Cells
were then washed with PBS and stained with a viability dye
(eFluor 780; 1:1000 dilution; Thermo Fisher, Hemel Hempstead,
UK) alongside an Fc receptor blockade (TruStain, 1 lg/mL;
Biolegend London, UK) for 20 min at 4 °C. Following this, cells
were washed in flow cytometry buffer and then fixed in 100 lL
BD Cytofix (Becton Dickinson, Oxford, UK) for 30 min at 4 °C.
Cells were washed and then stained with the following antibodies
at optimized concentrations for 45 min at 4 °C: CD3-FITC, CD4-
PerCP-Cy5.5, CD8-Alexa Fluor 700, IFN-c-PE Dazzle, IL-2-PE, IL-
17A-PE-Cy7 and TNF-a-APC (all from Biolegend). Fluorescence
minus one and PMA/ionomycin-stimulated cells were used to
determine gating boundaries and serve as positive controls. Cells
were then washed twice with permeabilization buffer and flow
cytometry buffer and then acquired on a LSR II (Beckton
Dickinson, Oxford, UK) instrument.
Immune responses to D-PIGS in human adenoid–tonsillar
tissue culture ex vivo
Adenoids and palatine tonsils were obtained from patients (aged
3–30 years) who underwent the adenoidectomy and/or tonsil-
lectomy due to upper airway obstruction at Liverpool Alder Hey
Children’s Hospital and Royal Liverpool and Broadgreen University
Hospitals (REC approval reference: 14/SS/1058). Written informed
consent was obtained from each patient. Adenoid–tonsillar
mononuclear cells (MNCs) were isolated following Ficoll gradient
centrifugation. For detection of T-cell proliferative responses, the
MNCs were stained with carboxyfluorescein succinimidyl ester
(CFSE), followed by cell stimulation with the D-PIGS (25 lg/mL) or
with cEDIII antigen alone (5 lg/mL). At day 3, cell culture
supernatants were collected for IFN-c analysis by ELISA. At day 5,
flow cytometry was performed to analyse CD4+ and CD8+ T-cell
proliferative responses using CFSE (5(6)-carboxyfluorescein N-
hydroxysuccinimidyl ester) cell tracing (Zhang et al., 2007).
Lymphocyte population was first gated using typical forward
and side scatter properties as indicated in Figure S6 (which
typically gave a viability greater >95% confirmed by propidium
iodide staining). Singlet population was gated and followed by
sequential staining for CD3/CD4/CD8/IFN-c as shown. Flowjo
software was used for flow data analysis. For detection of B-cell
antibody production, tonsillar MNCs were stimulated by the
vaccines or antigens for up to 2 weeks. Cell culture supernatants
were harvested and analysed by a standard ELISA procedure as
described previously (Zhang et al., 2006) for cEDIII antigen-
specific IgG antibody responses.
Additional methods
Binding of D-PIGS to U937 monocytic cells and C1q in ELISA
(Appendix S1), humoral responses analysis in sera (Appendix S2)
and T-cell proliferation assay and IFN-c measurement
(Appendix S3) are described in supportive information file.
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Statistical analysis
The cell culture-based assays were performed in triplicate, and the
values (from a representative experiment of typically 3 performed)
are shown as the mean  standard deviation. For immunization
experiments, five animals were used per group (in two indepen-
dent experiments). For all assays which had more than two
experimental variables, Dunnett’s multiple comparison test was
used. GraphPad Prism v.7 (GraphPad Software Inc., La Jolla, CA)
software was used for statistical analysis, and the differences
were significant when the P value was 0.05 or less.
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